A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors-Reference-Cited by-同舟云学术

A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors

Published:2022-10-26 Issue:6 Volume:90 Page:523-529
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Kitano Shigehisa^ORCID,Fujiwara Yutaka,Shimizu Toshio,Iwasa Satoru,Yonemori Kan,Kondo Shunsuke,Shimomura Akihiko,Koyama Takafumi,Ebata Takahiro,Ikezawa Hiroki,Hayata Nozomi,Minoshima Yukinori,Miura Takuma,Kubota Tomoki,Yamamoto Noboru

Funder

Eisai Inc., Nutley, NJ, USA

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00280-022-04480-w.pdf

Reference18 articles.

1. Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M (2008) Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 14:5459–5465. https://doi.org/10.1158/1078-0432.CCR-07-5270

2. Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, Uenaka T, Asada M (2008) E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 122:664–671. https://doi.org/10.1002/ijc.23131

3. Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, Minoshima Y, Iwata M, Funahashi Y (2014) Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 2014:638747. https://doi.org/10.1155/2014/638747

4. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372:621–630. https://doi.org/10.1056/NEJMoa1406470

5. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391:1163–1173. https://doi.org/10.1016/S0140-6736(18)30207-1

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer;Frontiers in Immunology;2023-10-16

2. Immunotherapy through the Lens of Non-Small Cell Lung Cancer;Cancers;2023-05-30